18th National and 3rd International Conference of Iranian Biophysical chemistry

هجدهمین همایش ملی و سومین همایش بین المللی بیوشیمی فیزیک ایران

25-26 Des, 2024, University of Hormozgan

۶-۵ دی ماه ۱۴۰۳، دانشگاه هرمزگان

The Power of Microbial Proteins in Clinical Diagnostics: A Metaproteomic Approach

Kaveh Kavousi [1]* , Leila Ghanbari-Maman[1], Anna Meyfour[2]

1. Laboratory of Complex Biological systems and Bioinformatics (CBB), Department of Bioinformatics, Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran.
2. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Metaproteomics, the study of all proteins expressed by a microbial community, is revolutionizing clinical diagnostics by providing a deeper understanding of host-microbiome interactions. Microbial proteins serve as critical indicators of disease, offering insights into complex pathologies that traditional biomarkers often miss [1]. This study explores the potential of gut microbiome metaproteomics for diagnosing pediatric Inflammatory Bowel Disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC) [2,3].

We demonstrate that microbial protein profiles provide superior diagnostic accuracy compared to conventional methods. By applying machine learning algorithms to metaproteomic data, we developed a diagnostic panel capable of distinguishing between CD and UC with high precision. This non-invasive approach offers a promising alternative for diagnosing IBD, particularly in children where current procedures can be challenging.

Our findings highlight the broader significance of omics data, particularly microbiome metaproteome, in modern medicine [4,5]. Metaproteomic analysis not only aids in accurate diagnosis but also paves the way for personalized medicine. By understanding the functional changes within the microbiome, clinicians can tailor treatments and improve patient outcomes. This study underscores the transformative power of metaproteomics in clinical settings, with potential applications extending beyond IBD to various complex diseases.

Key words: Metaproteomics, Complex Diseases, Diagnostic Biomarkers, Gut Microbiome, Machine Learning

References

[1] K Kavousi et al., "CAMAMED: a pipeline for composition-aware mapping-based analysis of metagenomic data", NAR Genomics and Bioinformatics, vol. 3, no. 1, 2021.

[2] S. C. Ng et al., "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies," The Lancet, vol. 390, no. 10114, 2017.

[3] M. Olfatifar et al., "The emerging epidemic of inflammatory bowel disease in Asia and Iran by 2035: A modeling study," BMC Gastroenterol, vol. 21, no. 1, 2021.

[4] A. Vaiopoulou et al., "Serum protein profiling of adults and children with crohn disease," J Pediatr Gastroenterol Nutr, vol. 60, no. 1, 2015.

[5] A. E. Starr et al., "Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC," *Gut*, vol. 66, no. 9, 2017.